Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - etacrynic acid -

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - etacrynic acid 50mg - tablet - 50 mg - active: etacrynic acid 50mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch purified talc

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - etacrynic acid - tablets

Australia - English - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - magnesium amino acid chelate,manganese amino acid chelate,pyridoxine hydrochloride,zinc amino acid chelate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 5000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 26 november 2001: prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism, coronary or venous thrombosis and occlusive vascular disease. as a low-dose regimen for the prevention of thromboembolic complications arising as a result of cardiac and arterial surgery. as an anticoagulant during blood transfusions, extracorporeal circulation, dialysis and other perfusion techniques and in blood samples for laboratory purposes.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - heparin sodium, quantity: 1000 iu/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 26 november 2001: prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism, coronary or venous thrombosis and occlusive vascular disease. as a low-dose regimen for the prevention of thromboembolic complications arising as a result of cardiac and arterial surgery. as an anticoagulant during blood transfusions, extracorporeal circulation, dialysis and other perfusion techniques and in blood samples for laboratory purposes.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vancomycin hydrochloride, quantity: 128 mg (equivalent: vancomycin, qty 125 mg) - capsule - excipient ingredients: iron oxide red; gelatin; indigo carmine; titanium dioxide; macrogol 6000; iron oxide yellow - this product accepted for registration as 'currently supplied' at the time of commencement of the act. revisions of product information was approved as specified in the letter of 13 august 1992 from dr alex proudfoot advising of approval for registration of the goods. indicated for the treatment of staphylococcal enterocolitis and antibiotic - associated pseudomembranous colitis produced by c. difficile.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - vancomycin hydrochloride, quantity: 256 mg (equivalent: vancomycin, qty 250 mg) - capsule - excipient ingredients: iron oxide black; titanium dioxide; indigo carmine; iron oxide red; gelatin; macrogol 6000 - this product accepted for registration as 'currently supplied' at the time of commencement of the act. revision of product information was approved as specified in the letter of 13 august 1992 from dr alex proudfoot advising of approval for registration of the goods. indicated for staphylococcal enterocolitis and antibiotic - associated pseudomembranous colitis produced by c. difficile.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - gentamicin sulfate - solution for injection - 20 mg/2ml - other aminoglycosides; gentamicin

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tobramycin, quantity: 40 mg/ml - injection, solution - excipient ingredients: sulfuric acid; sodium hydroxide; water for injections; disodium edetate; sodium bisulfite - tobramycin is indicated in the treatment of the following serious infections caused by susceptible micro-organisms: - central nervous system infections, including meningitis; septicaemia and neonatal sepsis; gastro-intestinal infections, including peritonitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis; lower respiratory tract infections, including pneumonia, bronchopneumonia and acute bronchitis; bone, skin and skin structure infections, including burns.,tobramycin may be considered in serious staphylococcal infections for which penicillin or other less potentially toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgement indicate its use. aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes or urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity.,bacterial cultures should be obtained prior to and during treatment to isolate and identify aetiologic organisms and to test their susceptibility to tobramycin. if susceptibility tests show that the causative organism is resistant to tobramycin, other appropriate therapy should be instituted. in patients in whom gram negative septicaemia, neonatal sepsis, or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. the decision to continue tobramycin therapy should be based upon the results of susceptibility studies, severity of the infection, and the important additional concepts discussed under precautions.